Aardvark Therapeutics Inc
AARDBuild a strategy around AARD
Aardvark Therapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue pre-clinical biotech burning 45.2M TTM cash (-45.1M FCF) with 39.3M cash remaining - ~10 months runway at current burn rate.[Free Cash Flow TTM]
- R&D spend of 42.7M TTM represents 80% of operating expenses, indicating pipeline-focused investment vs G&A bloat.[Research and Development TTM]
- Near-zero leverage (0.004 debt/equity) with 118.5M working capital provides flexibility for dilutive financing.[Debt to Equity]
Watch Triggers
- Cash and Equivalents: Falls below 25M or rises via financing — Financing announcement imminent if cash drops; terms reveal market confidence
- Research and Development TTM: Increases >20% or decreases >30% — Signals pipeline acceleration or cash preservation mode
- Issuance of Capital Stock: Any non-zero value — Dilution event - watch pricing vs current 2.3x book
Bull Case
Trading at 2.3x book (286M mkt cap vs 122M equity) - modest premium for pre-revenue biotech if pipeline advances.
Clean balance sheet (0.5M debt, 118M working capital) maximizes financing optionality and partnership leverage.
Bear Case
Sub-12 month cash runway with zero revenue makes near-term dilution virtually certain - timing/terms unknown.
ROE -13.3%, ROIC -13.3% reflect capital destruction; binary clinical outcomes determine equity value.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage AARD's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Capital raise required within 12 months - dilution or partnership announcement likely catalyst.
- 39.3M cash vs 45M annual burn = sub-12mo runway
- No revenue to offset cash consumption
- 29.3M investment sales in TTM suggests liquidity management
Valuation Context
Caveats
AARD Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$98.39M | — | ||
$36.29M | — | ||
0.00 | — | ||
$0 | — | ||
$-3.21 | — | ||
0% | — | ||
0% | — | ||
$-61.75M | — | ||
-58.8% | -40.4% | — | |
Beta 5Y (Monthly) | unknown | — |
AARD Dividend History
AARD Stock Splits
AARD SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
05/07/26 | 03/31/26 | 10-Q | |
03/23/26 | 12/31/25 | 10-K | |
11/13/25 | 09/30/25 | 10-Q | |
08/13/25 | 06/30/25 | 10-Q | |
05/14/25 | 03/31/25 | 10-Q | |
03/31/25 | 12/31/24 | 10-K | |
02/13/25 | 09/30/24 | 424B4 | |
06/30/24 | 06/30/24 | DRS | |
10/24/24 | 06/30/24 | DRS | |
05/14/25 | 03/31/24 | 10-Q | |
02/13/25 | 12/31/23 | 424B4 | |
09/30/23 | 09/30/23 | Unknown | -- |